These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 38717605)
21. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. Trigo JM; Soliman A; Quilty LC; Fischer B; Rehm J; Selby P; Barnes AJ; Huestis MA; George TP; Streiner DL; Staios G; Le Foll B PLoS One; 2018; 13(1):e0190768. PubMed ID: 29385147 [TBL] [Abstract][Full Text] [Related]
22. A Survey of Payer Perspectives on Cannabis Use Disorder. Kiselica AM; Duhig A; Montoya I; Skolnick P; Floyd J; Byars C Subst Use Misuse; 2018 Nov; 53(13):2257-2264. PubMed ID: 29927691 [TBL] [Abstract][Full Text] [Related]
23. Screening Medications for the Treatment of Cannabis Use Disorder. Panlilio LV; Justinova Z; Trigo JM; Le Foll B Int Rev Neurobiol; 2016; 126():87-120. PubMed ID: 27055612 [TBL] [Abstract][Full Text] [Related]
25. Exploring opportunities for drug repurposing and precision medicine in cannabis use disorder using genetics. Greco LA; Reay WR; Dayas CV; Cairns MJ Addict Biol; 2023 Aug; 28(8):e13313. PubMed ID: 37500481 [TBL] [Abstract][Full Text] [Related]
26. Predictors of Topiramate Tolerability in Heavy Cannabis-Using Adolescents and Young Adults: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial. Gray JC; Treloar Padovano H; Wemm SE; Miranda R J Clin Psychopharmacol; 2018 Apr; 38(2):134-137. PubMed ID: 29424802 [TBL] [Abstract][Full Text] [Related]
27. The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal. Brezing CA; Levin FR Neuropsychopharmacology; 2018 Jan; 43(1):173-194. PubMed ID: 28875989 [TBL] [Abstract][Full Text] [Related]
28. Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report. Cooper K; Chatters R; Kaltenthaler E; Wong R Health Technol Assess; 2015 Jul; 19(56):1-130. PubMed ID: 26202542 [TBL] [Abstract][Full Text] [Related]
29. Management of comorbid bipolar disorder and substance use disorders. Salloum IM; Brown ES Am J Drug Alcohol Abuse; 2017 Jul; 43(4):366-376. PubMed ID: 28301219 [TBL] [Abstract][Full Text] [Related]
30. Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents. Nielsen S; Sabioni P; Gowing L; Le Foll B Handb Exp Pharmacol; 2020; 258():355-372. PubMed ID: 31375922 [TBL] [Abstract][Full Text] [Related]
31. Pharmacotherapies for cannabis dependence. Marshall K; Gowing L; Ali R; Le Foll B Cochrane Database Syst Rev; 2014; 12(12):CD008940. PubMed ID: 25515775 [TBL] [Abstract][Full Text] [Related]
33. Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder. Lee DC; Schlienz NJ; Peters EN; Dworkin RH; Turk DC; Strain EC; Vandrey R Drug Alcohol Depend; 2019 Jan; 194():500-517. PubMed ID: 30530238 [TBL] [Abstract][Full Text] [Related]
34. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Cornelius JR; Bukstein OG; Douaihy AB; Clark DB; Chung TA; Daley DC; Wood DS; Brown SJ Drug Alcohol Depend; 2010 Nov; 112(1-2):39-45. PubMed ID: 20576364 [TBL] [Abstract][Full Text] [Related]
35. Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder. Tomko RL; Baker NL; Hood CO; Gilmore AK; McClure EA; Squeglia LM; McRae-Clark AL; Sonne SC; Gray KM Psychopharmacology (Berl); 2020 Feb; 237(2):479-490. PubMed ID: 31712969 [TBL] [Abstract][Full Text] [Related]
36. Repurposing ketamine to treat cocaine use disorder: integration of artificial intelligence-based prediction, expert evaluation, clinical corroboration and mechanism of action analyses. Gao Z; Winhusen TJ; Gorenflo M; Ghitza UE; Davis PB; Kaelber DC; Xu R Addiction; 2023 Jul; 118(7):1307-1319. PubMed ID: 36792381 [TBL] [Abstract][Full Text] [Related]
37. Exercise as an adjunctive treatment for cannabis use disorder. Brellenthin AG; Koltyn KF Am J Drug Alcohol Abuse; 2016 Sep; 42(5):481-489. PubMed ID: 27314543 [TBL] [Abstract][Full Text] [Related]
38. Influence of tiagabine maintenance on cannabis effects and related behaviors in daily cannabis users. Wesley MJ; Westgate PM; Stoops WW; Kelly TH; Hays LR; Lile JA Exp Clin Psychopharmacol; 2018 Jun; 26(3):310-319. PubMed ID: 29863387 [TBL] [Abstract][Full Text] [Related]
39. Non-abstinent treatment outcomes for cannabis use disorder. Levin FR; Mariani JJ; Choi CJ; Basaraba C; Brooks DJ; Brezing CA; Pavlicova M Drug Alcohol Depend; 2021 Aug; 225():108765. PubMed ID: 34087745 [TBL] [Abstract][Full Text] [Related]
40. Decreased drinking in adults with co-occurring cannabis and alcohol use disorders in a treatment trial for marijuana dependence: Evidence of a secondary benefit? Dunn HK; Litt MD Addict Behav; 2019 Dec; 99():106051. PubMed ID: 31487577 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]